120 related articles for article (PubMed ID: 20210915)
41. Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease.
Neumiller JJ; Alicic RZ; Tuttle KR
J Am Soc Nephrol; 2017 Aug; 28(8):2263-2274. PubMed ID: 28465376
[TBL] [Abstract][Full Text] [Related]
42. Management of hyperglycemia in patients with chronic kidney disease.
Aires Neto P; Gomes HV; Campos M
J Nephrol; 2013; 26(4):629-35. PubMed ID: 23807643
[TBL] [Abstract][Full Text] [Related]
43. Management Strategies for Patients with Diabetic Kidney Disease and Chronic Kidney Disease in Diabetes.
Yakush Williams JK
Nurs Clin North Am; 2017 Dec; 52(4):575-587. PubMed ID: 29080579
[TBL] [Abstract][Full Text] [Related]
44. Management of diabetes-related chronic kidney disease.
Reddy N
Nephrol News Issues; 2011 Jun; 25(7):20, 22. PubMed ID: 21736131
[No Abstract] [Full Text] [Related]
45. Variation of Pharmacokinetic Profiles of Some Antidiabetic Drugs from Nanostructured Formulations Administered Through Pulmonary Route.
Mukherjee B; Paul P; Choudhury A; Bhattacharya S; Maji R; Dutta L
Curr Drug Metab; 2016; 17(3):271-8. PubMed ID: 26467065
[TBL] [Abstract][Full Text] [Related]
46. Medication dosing in patients with chronic kidney disease.
Zuber K; Liles AM; Davis J
JAAPA; 2013 Oct; 26(10):19-25. PubMed ID: 24201917
[TBL] [Abstract][Full Text] [Related]
47. Overcoming challenges in Type 2 diabetes management to improve patient outcomes.
Brown MT; LeRoith D
Expert Rev Endocrinol Metab; 2010 Sep; 5(5):741-751. PubMed ID: 30764026
[TBL] [Abstract][Full Text] [Related]
48. [Thiazolidinediones].
Nakamura T; Ueda Y
Nihon Rinsho; 2010 Nov; 68 Suppl 9():476-80. PubMed ID: 21661186
[No Abstract] [Full Text] [Related]
49. Updates on the management of diabetes in dialysis patients.
Rhee CM; Leung AM; Kovesdy CP; Lynch KE; Brent GA; Kalantar-Zadeh K
Semin Dial; 2014 Mar; 27(2):135-45. PubMed ID: 24588802
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2013 May; 9(5):529-50. PubMed ID: 23461781
[TBL] [Abstract][Full Text] [Related]
51. Frequency, types and predictors of drug therapy problems among non-dialysis chronic kidney disease patients at a tertiary care hospital in Pakistan.
Hayat M; Ahmad N; Mohkumuddin S; Ali Khan SL; Khan AH; Haq NU; Haque N; Khan A
PLoS One; 2023; 18(4):e0284439. PubMed ID: 37058504
[TBL] [Abstract][Full Text] [Related]
52. Fasting Ramadan in Chronic Kidney Disease (CKD), Kidney Transplant and Dialysis Patients: Review and Update.
Habas E; Errayes M; Habas E; Farfar KL; Alfitori G; Habas AE; Rayani A; Elzouki AY
Cureus; 2022 May; 14(5):e25269. PubMed ID: 35755525
[TBL] [Abstract][Full Text] [Related]
53. Analyzing Medical Research Results Based on Synthetic Data and Their Relation to Real Data Results: Systematic Comparison From Five Observational Studies.
Reiner Benaim A; Almog R; Gorelik Y; Hochberg I; Nassar L; Mashiach T; Khamaisi M; Lurie Y; Azzam ZS; Khoury J; Kurnik D; Beyar R
JMIR Med Inform; 2020 Feb; 8(2):e16492. PubMed ID: 32130148
[TBL] [Abstract][Full Text] [Related]
54. The Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients.
Kukla A; Hill J; Merzkani M; Bentall A; Lorenz EC; Park WD; D'Costa M; Kudva YC; Stegall MD; Shah P
Transplant Direct; 2020 Feb; 6(2):e524. PubMed ID: 32095510
[TBL] [Abstract][Full Text] [Related]
55. Temporal Trends of Severe Hypoglycemia and Subsequent Mortality in Patients with Advanced Diabetic Kidney Diseases Transitioning to Dialysis.
Hsiao CC; Tu HT; Lin CH; Chen KH; Yeh YH; See LC
J Clin Med; 2019 Mar; 8(4):. PubMed ID: 30934740
[TBL] [Abstract][Full Text] [Related]
56. Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis.
Ye J; Deng G; Gao F
Drug Des Devel Ther; 2018; 12():901-909. PubMed ID: 29719376
[TBL] [Abstract][Full Text] [Related]
57. Risks of Metformin in Type 2 Diabetes and Chronic Kidney Disease: Lessons Learned from Taiwanese Data.
Rhee CM; Kovesdy CP; Kalantar-Zadeh K
Nephron; 2017; 135(2):147-153. PubMed ID: 27760420
[TBL] [Abstract][Full Text] [Related]
58. Update on the treatment of type 2 diabetes mellitus.
Marín-Peñalver JJ; Martín-Timón I; Sevillano-Collantes C; Del Cañizo-Gómez FJ
World J Diabetes; 2016 Sep; 7(17):354-95. PubMed ID: 27660695
[TBL] [Abstract][Full Text] [Related]
59. Haemodialysis-induced hypoglycaemia and glycaemic disarrays.
Abe M; Kalantar-Zadeh K
Nat Rev Nephrol; 2015 May; 11(5):302-13. PubMed ID: 25848881
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.
Scheen AJ
Clin Pharmacokinet; 2015 Jan; 54(1):1-21. PubMed ID: 25331711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
